Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Host immune receptors recognizing the SARS-CoV-2 spike protein are a diverse group of pattern recognition receptors (PRRs) and cell-surface molecules that identify the viral spike (S) glycoprotein to initiate or modulate the host immune response. This group includes Toll-like receptors, notably TLR4 and TLR2, which recognize the S1 and S2 subunits of the spike protein to trigger the NF-κB signaling pathway and the subsequent release of pro-inflammatory cytokines such as IL-6 and TNF-α (Zhao et al., 2021; Khan et al., 2021). Additionally, C-type lectin receptors (CLRs) such as DC-SIGN (CD209), L-SIGN (CLEC4M), and MGL (CLEC10A) bind to the glycans on the spike protein, potentially acting as alternative attachment factors that facilitate viral entry or promote the infection of susceptible cells (Amraei et al., 2021; Lu et al., 2021). While these interactions are essential for the innate detection of the pathogen, their dysregulation is a major contributor to the hyper-inflammatory state or "cytokine storm" observed in severe COVID-19 cases (Nature Reviews Immunology, 2021). Therapeutic strategies targeting these receptors, such as the TLR4 antagonist Eritoran or various experimental glycomimetics, aim to dampen pathological inflammation and block non-ACE2 mediated viral pathways. These interventions must be carefully balanced to reduce tissue damage without compromising the host's ability to clear the viral infection.
Competitive antagonism of pattern recognition receptors to block viral protein-induced inflammatory signaling and inhibit lectin-mediated viral attachment.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Host immune receptors recognizing SARS-CoV-2 spike protein.